Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma:Practical considerations in routine clinical practice

作     者：Ankit Jain Shivakumar Chitturi Geoffrey Peters Desmond Yip 

作者机构：Department of Medical OncologyThe Canberra HospitalGarran 2605ACTAustralia ANU Medical SchoolAustralian National UniversityCanberra 0200ACTAustralia Gastroenterology and Hepatology UnitCanberra HospitalCanberra 2605ACTAustralia 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2021年第13卷第9期

页      面：1132-1142页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Hepatocellular carcinoma Atezolizumab Bevacizumab Immunotherapy Child Pugh cirrhosis Anti-angiogenic therapy 

摘      要：Hepatocellular carcinoma(HCC)is the most common primary liver *** advanced HCC,sorafenib was considered the standard of care for more than ten *** the atezolizumab and bevacizumab combination has become standard of care for these patients without contraindications to either immune checkpoint inhibitors or antiangiogenic *** now review the practical aspects of the atezolizumab and bevacizumab combination,including current evidence,indications,contraindications,management of adverse events,sequencing of this combination,areas of current knowledge gaps and future areas of active clinical research of this combination for busy clinicians in clinical practice.